Latest filing published 24 Jan 2022 for InMed Pharmaceuticals Inc., €4,795.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Bruce Colwill: trading record in brief
All filings by Bruce Colwill on record concern InMed Pharmaceuticals Inc., in the capacity of finance chief. We count 2 filings; the first trade dates from 28 September 2021 and the latest from 24 January 2022.
The open-market record is one-sided, with 2 purchases worth €12k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2022 to date brings 1 purchase and no sales.
On 24 January 2022 came the latest disclosure, an open-market purchase for €4,795 in InMed Pharmaceuticals Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Bruce Colwill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$1.087738.8% of flowCommon StockSEC:0001213900-22-003286:0Canonical exit: 24 Apr 2022 (T+90)
- 5,000 shares@ US$1.76861.2% of flowCommon StockSEC:0001213900-21-050521:0Canonical exit: 27 Dec 2021 (T+90)
2 of 2 declarations
